ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression...

Area of Science:

• Oncology
• Cancer Biology
• Immunotherapy

Background:

• Delta-like-ligand 4 (DLL4) pathway blockade complements VEGF inhibitors for enhanced anti-cancer effects.
• A bispecific antibody (ABL001) targeting both VEGF and DLL4 shows superior activity over single-target antibodies.
• The clinical efficacy of combining ABL001 with chemotherapy remains unexplored.

Purpose of the Study:

• To evaluate the combined effects of ABL001 and chemotherapy on tumor progression.
• To investigate the impact of ABL001 and chemotherapy combination on tumor vasculature and cell apoptosis.
• To determine if ABL001 combined with paclitaxel or irinotecan offers a superior therapeutic strategy.

Main Methods:

• Utilized human gastric and colon cancer xenograft models.
• Administered ABL001 as monotherapy or in combination with paclitaxel or irinotecan.
• Assessed tumor progression, tumor vessel regression, and tumor cell apoptosis.

Main Results:

• Combination therapy demonstrated synergistic inhibition of tumor progression compared to monotherapy.
• Enhanced tumor vessel regression and increased apoptotic tumor cells were observed with combination treatment.
• Tumor vessel normalization is suggested as a mechanism underlying the combination's efficacy.

Conclusions:

• Combination of ABL001 with paclitaxel or irinotecan presents a promising synergistic anti-cancer strategy.
• This combination therapy could offer improved clinical outcomes for cancer patients.
• Targeting both VEGF and DLL4 pathways concurrently with chemotherapy warrants further clinical investigation.